News

At first glance, this finding may seem surprising. Only three GMOs obtained through new techniques of genetic modification are currently being cultivated and their harvest commercialised. The many promises of their benefits for health, the environment, and “competitiveness”, as well as the argument that they are already deregulated in many countries around the world, would suggest that these “miracle” products would have been more widely adopted. Clearly, this is not the case.

Under the guise of making the continent a world leader in “life sciences”, the European Commission has confirmed its clearly pro-industry vision in its strategy published in early July. With a resolutely competitiveness-focused approach, it minimises the potential consequences for other social actors.

In 2024, the European Union once again recorded alerts of GMO contamination. Of the 24 alerts, the vast majority concerned unauthorised GM rice, but also papaya, soybean, flax and corn. Two cases of contamination by genetically modified microorganisms were also reported, one of which even forced the Belgian authorities to issue a public statement recalling a product. In three cases, the nature of the illegal GMO was not specified.

The need to be able to detect and identify GMOs obtained through new genetic modification techniques is a request that is being made more and more frequently. Following in the footsteps of associations, farmers’ unions, organic and non-GMO producers and processors, as well as supermarkets, it is now the turn of some laboratories specializing in analyses to make such a demand. At a time when European legislators are discussing the possible complete deregulation of such GMOs, these positions could carry more and more weight.

Animal proteins without animalsMilk proteins without cows, fish without fish, meat without animals and even egg proteins without eggs or chickens: welcome to the realm of “precision fermentation” for our future food. Three start-ups in the sector have obtained approval for their milk-free milk proteins from the US health authorities, enabling them to sell them to food manufacturers.The industry and certain institutions are presenting these innovations as a step forward in reducing the carbon impact of livestock farming and meeting the food needs of human populations. Above all, it is a promising market: these “advances” are already attracting investors.

In an article published in April 2025, Euronews highlights “new genomic techniques” using the example of a wheat genetically modified by Crispr/Cas9 in the UK. This wheat, developed by a team of biologists from Rothamsted Research at the University of Bristol, has been tested in a field north of London since October 2021. Although this trial is being carried out without any environmental, agricultural or health precautions, it does provide a good showcase for potential investors.

Three groups of French and European organizations have publicly called on political leaders not to abolish labelling and traceability requirements for GMOs produced using new techniques. In their view, maintaining these obligations is the only way to guarantee freedom of choice for farmers and consumers, and to protect the seed and peasant sectors from contamination and attempts by multinationals to take control of living organisms.

At the beginning of April, the Tirpaa again discussed the expansion of the list of crops covered by the multilateral system and the revision of the contract governing their use. While some Member States of the Treaty are invoking the need to guarantee global food security, fears are being voiced that there will be a drift in widespread access to peasant and traditional seeds. This would facilitate their patenting, without any real sharing of the benefits, to the detriment of the countries of the “South” and the rights of the peasants.

The European Commission’s postponement of its “biotech law” until the end of 2026 is raising questions. Presented as a future “regulation”, this law must be coordinated with other legal acts still under discussion, in particular the one on new genomic techniques (NGT). But the regulation on health data (known as “EHDS”), adopted in February 2025, could also be a reason for this postponement.